We have an inpatient opening at Carilion Clinic to join our ID Pharmacy Team! We are involved in all of our hospitals, great physician collab, amazing ID PGY2s to train and Southwest VA is gorgeous! Apply before May 21st! Hit me up with any questions! https://t.co/GJAdlqsxPt
@JGPharmD @amyfaithho @HollyBiology Literally the only time my “Dr.” title is used is when my amazing physician colleagues introduce me to patients. I haven’t used it in 10 years. Agree this is a non problem, and is kinda embarrassing it’s being double downed.
Pursuing ID PGY2 in Phase II of the match?!? We still have a spot! @CRMHRxResidency.
Come check us out Tuesday 3/21 for an informational session via Zoom. Drop in anytime from 4-7pm.
https://t.co/tqzqcZcm6y
Program Details: https://t.co/jUKfU7RZLd
#IDTwitter#RxTwitter
After an extensive search I’m seeing 4-6 weeks for recordings but no CE. There has to be a way to provide CE to folks doing PPS and paying for the whole meeting.
Is it true there are no session recordings or virtual CE from midyear @ASHPOfficial? This is a standard expectation for a $795 meeting in 2022. Particularly when you require attendees who have to spend most of their time in PPS to still purchase a full meeting registration.
@PatriciaSH123@ABsteward@InfectDis_Ther Pharma supports independent researchers all the time. Being one of the authors, we are all clinicians and have no dedicated research time. Knowing we had a process we wanted to share it was made feasible as an organizational priority with funding.
🆕⚡⚡@InfectDis_Ther
Implementation of fidaxomicin treatment pathway was associated with
🔽 CDI recurrences
🔽CDI-related readmissions within 30 & 90d
🔼 clinical cure and sustained response at 90-d post Rx
Overall cost-savings to a US Hospital system https://t.co/HqyZaMRqvk
If an insurance company says to use fluconazole instead of our prescribed posaconazole for HISTO, is there a way to report them for medical malpractice? Asking for a VERY frustrated friend.
Progress on the Lyme disease vaccine front:
Press release data suggests that vaccine candidate VLA15 was safe and immunogenic in a Phase 2 study & there are plans to move ahead with a Phase 3 clinical trial.
Fingers tightly crossed.
https://t.co/DHPwpJoUnA